Company Encyclopedia
View More
name
Alcon
ALC.US
Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. It operates through two segments, Surgical and Vision Care. The company offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures.
330.79 B
ALC.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
Health Care SuppliesIndustry
Industry Ranking8/42
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE4.82%C
    • Profit Margin10.28%B
    • Gross Margin55.78%B
  • Growth ScoreC
    • Revenue YoY4.34%C
    • Net Profit YoY-9.82%D
    • Total Assets YoY3.83%C
    • Net Assets YoY3.27%C
  • Cash ScoreB
    • Cash Flow Margin972.78%B
    • OCF YoY4.34%C
  • Operating ScoreD
    • Turnover0.33D
  • Debt ScoreB
    • Gearing Ratio29.93%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Is The Market Missing Alcon’s Rebound After Recent Product Expansion News?

    Alcon's stock has shown signs of recovery, gaining 8.4% in the last month despite a 17.8% decline over the past year. Recent product expansions and strategic investments have improved market sentiment. A Discounted Cash Flow analysis suggests Alcon is undervalued by 31%, while its PE ratio is slightly above the industry average, indicating the stock is priced in line with its fundamentals. The market may be underestimating Alcon's long-term cash generation potential.

    Simplywall·
    US
    ALC
    -1.30%
    Simplywall·
    US
    ALC
    -1.30%

    Australia's Tetratherix soars on Alcon funding

    ** Shares of Australia's Tetratherix rise as much as 10.1% to A$4.24, their highest level since mid-November** Stock set for its strongest session in six weeks, if current trends hold** Regenerative biomaterials maker says BioOptix, which is co's JV partner has entered agreement with Alcon Research** Under agreement, Alcon Research to provide funding to speed up commercialization of products from Tetramatrix platform technology** Tetramatrix platform technology is a biomaterial platform which creates implantable products for diverse clinical needs - co's website** Stock up near 25% since it listed on June 30

    Reuters·
    US
    ALC
    -1.30%
    Reuters·
    US
    ALC
    -1.30%

    Tetratherix Says BioOptix Enters Agreement With Alcon Research

    Tetratherix Ltd :BIOOPTIX ALCON UPDATEBIOOPTIX ENTERS AGREEMENT WITH ALCON RESEARCHALCON TO PROVIDE MILESTONE-BASED DEVELOPMENT FUNDING TO COMPLETE RANGE OF SPECIFIC PRECLINICAL STUDIES

    Reuters·
    US
    ALC
    -1.30%
    Reuters·
    US
    ALC
    -1.30%

    10:15 ET Intraocular Lens Market worth $6.17 billion by 2030 with 6.0% CAGR | MarketsandMarkets™

    The global Intraocular Lens Market is projected to grow from $4.38 billion in 2024 to $6.17 billion by 2030, with a CAGR of 6.0%. Growth is driven by the prevalence of cataracts, aging populations, and advancements in lens technology. North America leads the market due to advanced infrastructure and favorable policies. Key players include Alcon, Johnson & Johnson, and HOYA Corporation. Challenges include high costs and limited reimbursement. MarketsandMarkets™ provides insights into this market's growth potential.

    prnewswire·
    US
    ALC
    -1.30%
    US
    JNJ
    -1.39%
    prnewswire·
    US
    ALC
    -1.30%
    US
    JNJ
    -1.39%

    Alcon (ALC) Gets a Buy from KeyBanc

    KeyBanc analyst Brett Fishbin reiterated a Buy rating on Alcon with a price target of $91.00. Fishbin, who covers the Healthcare sector, has an average return of -8.5% and a 41.51% success rate. Alcon also received a Buy rating from TR | OpenAI – 4o’s Jack Scalprey, while Morgan Stanley maintained a Hold rating.

    Tip Ranks·
    US
    ALC
    -1.30%
    Tip Ranks·
    US
    ALC
    -1.30%
    © 2025 Longbridge｜Disclaimer